SANO

Sanofi India Limited (SANOFI)

Market Closed
12 Dec, 10:00
XNSE XNSE
4,242. 20
-0.5
-0.01%
192.72B Market Cap
31.06 P/E Ratio
167% Div Yield
14,340 Volume
262.87 Eps
4,242.7
Previous Close
Day Range
4,225.6 4,269.4
Year Range
4,219.5 6,717
Want to track SANOFI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 74 days

Summary

SANOFI closed yesterday lower at ₹4,242.2, a decrease of 0.01% from Thursday's close, completing a monthly decrease of -2.7% or ₹117.8. Over the past 12 months, SANOFI stock lost -30.71%.
SANOFI pays dividends to its shareholders, with the most recent payment made on Nov 28, 2025. The next estimated payment will be in In 5 months on May 28, 2026 for a total of ₹75.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 25, 2026.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XNSE (INR).

SANOFI Chart

Similar

Doms Industries Ltd.
2,571.9
+1.54%
Ramkrishna Forgings Ltd.
516
-0.65%
Rainbow Children's Medicare Pvt. Ltd.
1,386.6
+0.5%
Marksans Pharma Ltd.
193.86
+1.02%
Esab India Ltd.
6,194
-2.63%

Sanofi India Limited (SANOFI) FAQ

What is the stock price today?

The current price is ₹4,242.20.

On which exchange is it traded?

Sanofi India Limited is listed on XNSE.

What is its stock symbol?

The ticker symbol is SANOFI.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 167%.

What is its market cap?

As of today, the market cap is 192.72B.

When is the next earnings date?

The next earnings report will release on Feb 25, 2026.

Has Sanofi India Limited ever had a stock split?

No, there has never been a stock split.

Sanofi India Limited Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Rodolfo Hrosz CEO
XNSE Exchange
INE058A01010 ISIN
IN Country
- Employees
7 Nov 2025 Last Dividend
23 Sep 1994 Last Split
- IPO Date

Overview

Sanofi India Limited is a prominent pharmaceutical company focused on manufacturing and trading a wide range of drugs and pharmaceutical products not only within India but also internationally, extending its reach to renowned markets such as Singapore. The company boasts an expansive portfolio of pharmaceutical products across multiple therapeutic domains including diabetes, cardiology, thrombosis, and more. Originally known as Aventis Pharma Limited, the entity underwent a rebranding to Sanofi India Limited in May 2012, marking a significant milestone in its history. With a foundation laid in 1956, Sanofi India Limited operates with its headquarters positioned in Mumbai, India, functioning under the parent company Hoechst GmbH. Furthermore, the company is known for its active engagement in exporting pharmaceutical products, showcasing its global significance in the pharmaceutical industry.

Products and Services

Sanofi India Limited offers a comprehensive array of pharmaceutical products spanning various therapeutic areas. The company's dedication to healthcare is reflected through its high-quality products, which include:

  • Lantus and Toujeo: Both brands are critical in the management of diabetes, providing patients with cutting-edge insulin treatments.
  • Clexane: A widely recognized brand in the area of thrombosis, offering solutions for blood clot prevention.
  • Amaryl: A trusted name in diabetes care, Amaryl facilitates effective blood sugar regulation.
  • Cardace: Well-regarded in the field of cardiology, Cardace is pivotal in managing high blood pressure and heart failure conditions.
  • Targocid: A vital antibiotic for treating serious infections, thereby playing a crucial role in the anti-infective therapeutic area.
  • Frisium: Catering to the central nervous system, Frisium is aimed at managing epilepsy and seizures.
  • Combiflam: A commonly used anti-inflammatory and analgesic medication, effective for pain relief.
  • DePura: Falling under the vitamins and minerals category, DePura is essential in maintaining overall health and well-being.
  • Allegra and Avil: Both brands are significant in the treatment of allergies, providing relief from allergic symptoms through their antihistamine properties.

These products are distributed through independent channels, ensuring their availability to a wide patient base. Furthermore, Sanofi India Limited's commitment to health extends beyond the domestic market, with a strong focus on exporting its pharmaceutical solutions, thereby contributing significantly to global health advancements.

Contact Information

Address: Sanofi House, Mumbai, India, 400072
Phone: 91 22 2803 2000